Search results for "staging"

showing 10 items of 740 documents

Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients

2014

Abstract Improved prognostic stratification of patients with TNM stage II colorectal cancer (CRC) is desired, since 20–30% of high-risk stage II patients may die within five years of diagnosis. This study was conducted to investigate REarranged during Transfection ( RET ) gene promoter CpG island methylation as a possible prognostic marker for TNM stage II CRC patients. The utility of RET promoter CpG island methylation in tumors of stage II CRC patients as a prognostic biomarker for CRC related death was studied in three independent series (including 233, 231, and 294 TNM stage II patients, respectively) by using MSP and pyrosequencing. The prognostic value of RET promoter CpG island methy…

MaleCpg island methylationOncologyCancer Researchmedicine.medical_specialtyColonColorectal cancerBiologyBioinformaticsCell Line TumorInternal medicineGeneticsmedicineHumansStage (cooking)Promoter Regions GeneticneoplasmsResearch ArticlesAgedNeoplasm StagingProportional hazards modelRectumStage II Colorectal CancerPromoterGeneral MedicineMethylationDNA MethylationMiddle AgedPrognosismedicine.diseasedigestive system diseasesOncologyDNA methylationMolecular MedicineCpG IslandsFemaleColorectal NeoplasmsMolecular Oncology
researchProduct

The Impact of Endoscopic Ultrasound and Computed Tomography on the TNM Staging of Early Cancer in Barrett's Esophagus

2006

Computed tomography (CT) and endoscopic ultrasound (EUS) are part of the regular staging protocol in esophageal cancer. The value of the two methods was assessed in patients with early cancer in Barrett's esophagus.One hundred consecutive patients (median age 64 yr, interquartile range [IQR] 58-72) with suspected early cancer in Barrett's esophagus who were referred to our hospital for endoscopic therapy were prospectively included in a standardized staging program with upper gastrointestinal endoscopy, EUS (7.5 MHz in all cases plus 12.5 or 20 MHz for elevated and/or depressed lesions), CT of the chest and upper abdomen, and abdominal ultrasonography. The results were summarized in accorda…

MaleEndoscopic ultrasoundmedicine.medical_specialtyEarly cancerEsophageal NeoplasmsAdenocarcinomadigestive systemEndosonographyBarrett EsophagusPredictive Value of TestsmedicineHumansProspective StudiesEsophagusneoplasmsAgedNeoplasm StagingHepatologymedicine.diagnostic_testbusiness.industryEsophageal diseaseUltrasoundGastroenterologyReproducibility of ResultsMiddle Agedmedicine.diseasedigestive system diseasesEndoscopystomatognathic diseasessurgical procedures operativemedicine.anatomical_structureBarrett's esophagusFemaleRadiologyTomographyTomography X-Ray ComputedbusinessThe American Journal of Gastroenterology
researchProduct

A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Cons…

2015

Abstract Background: Female sex hormones are known to have immunomodulatory effects. Therefore, reproductive factors and exogenous hormone use could influence the risk of multiple myeloma in women. However, the role of hormonal factors in multiple myeloma etiology remains unclear because previous investigations were underpowered to detect modest associations. Methods: We conducted a pooled analysis of seven case–control studies included in the International Multiple Myeloma Consortium, with individual data on reproductive factors and exogenous hormone use from 1,072 female cases and 3,541 female controls. Study-specific odds ratios and corresponding 95% confidence intervals (CI) were estima…

MaleEpidemiologymedicine.medical_treatmentPhysiology[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineRisk FactorsOdds RatioGonadal030212 general & internal medicineReproductive HistoryMultiple myelomaIncidenceMiddle AgedStatisticalPrognosis3. Good healthPostmenopauseContraceptionOncologyTransgender hormone therapy030220 oncology & carcinogenesisMeta-analysisRegression AnalysisFemaleMultiple MyelomaFactor AnalysisAdultHormone Replacement Therapy[SDV.CAN]Life Sciences [q-bio]/CancerArticle03 medical and health sciencesYoung AdultMeta-Analysis as TopicReproductive factors exogenous hormone use and risk of multiple myelomamedicineConfidence IntervalsHumansNeoplasm StagingSteroid Hormonesbusiness.industryCase-control studyOdds ratiomedicine.diseaseHormonesLogistic ModelsHormonal contraceptionCase-Control StudiesSample SizeImmunologyHormone therapybusinessHormoneFollow-Up StudiesMeta-Analysis
researchProduct

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by (18)FDG-PET/CT

2017

Abstract Objectives The objective of this study was to investigate fludeoxyglucose F 18 positron emission tomography/computed tomography ( 18 FDG-PET/CT) parameters as predictive of response after stereotactic ablative radiotherapy (SABR) for lung oligometastases. Methods The inclusion criteria of the current retrospective study were as follows: (1) lung oligometastases treated by SABR, (2) presence of 18 FDG-PET/CT before and after SABR for at least two subsequent evaluations, (3) Karnofsky performance status higher than 80, and (4) life expectancy longer than 6 months. All patients were treated with a biologically equivalent dose of at least 100 Gy with an alpha/beta ratio of 10. The foll…

MaleFludeoxyglucose F-18Lung Neoplasmsmedicine.medical_treatment18FDG-PET/CT; Lung malignancies; Predictive factors; SABR; Adenocarcinoma; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Carcinoma Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Radiosurgery; Oncology; Pulmonary and Respiratory MedicineSABR volatility model030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAblative case80 and overMedicineNon-Small-Cell LungSABRmedicine.diagnostic_test(18)FDG-PET/CTMiddle AgedPrognosisTumor Burdenmedicine.anatomical_structureLocalOncologyPositron emission tomography030220 oncology & carcinogenesisLymphatic MetastasisFemaleRadiologyPredictive factorsPulmonary and Respiratory Medicinemedicine.medical_specialtyLung malignanciesStandardized uptake value18FDG-PET/CTAdenocarcinomaRadiosurgery03 medical and health sciencesFluorodeoxyglucose F18HumansAgedNeoplasm StagingRetrospective StudiesLungbusiness.industryCarcinomaRetrospective cohort studyRadiation therapyNeoplasm RecurrenceSquamous CellRadiopharmaceuticalsbusinessNuclear medicineFollow-Up Studies(18)FDG-PET/CT; Lung malignancies; Predictive factors; SABR
researchProduct

Modified fronto-lateral laryngectomy in treatment of glottic T1(a-b) cancer with anterior commissure involvement

2010

Abstract Objective Evaluation of clinical and oncological safety of the modified fronto-lateral laryngectomy in the treatment of T1a-b glottic cancer. Methods Retrospective review of charts of patients managed with classical fronto-lateral laryngectomy or with our modified technique using a cervical fascia flap and a false cord flap to reconstruct the defect. Results No recurrence of cancer was observed in the present series and slight dysphonia was present in all cases. The patients managed with classical technique required a revision surgery for granulations or anterior synechia in 4 cases; those managed with modified technique did not need a second intervention. Conclusion The fronto-lat…

MaleGlottismedicine.medical_specialtymedicine.medical_treatmentLaryngectomyAnterior commissureCarcinomaHumansMedicineNeoplasm Invasivenesslarynx surgery cancer tumor voice fronto-lateral laryngectomy partial laryngectomyLaryngeal NeoplasmsSynechiaAgedNeoplasm StagingRehabilitationbusiness.industryCervical fasciaCancerGeneral MedicineMiddle Agedmedicine.diseaseSurgeryLaryngectomySettore MED/31 - OtorinolaringoiatriaOtorhinolaryngologyGlottic cancerCarcinoma Squamous CellFemaleSurgerybusinessAuris Nasus Larynx
researchProduct

Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

2013

Pemetrexed has been widely used in patients with advanced non-small cell lung cancer (NSCLC). The clinical relevance of polymorphisms of folate pathway genes for pemetrexed metabolism have not been fully elucidated yet. The aim of this study was to evaluate the expression levels of circulating miR-22, miR-24, and miR-34a, possibly involved in folate pathway, in NSCLC patients treated with pemetrexed compared with healthy controls and to investigate their impact on patient clinical outcomes. A total of 22 consecutive patients with advanced NSCLC, treated with pemetrexed-based chemotherapy and 27 age and sex matched healthy controls were included in this preliminary analysis. miR-22, miR-24, …

MaleGuanineSettore MED/06 - Oncologia MedicaPemetrexedMiddle AgedNeoplastic Cells CirculatingPrognosisBiomarkers PharmacologicalNon-Small Cell Lung CancerGene Expression Regulation NeoplasticMicroRNAsGlutamatesCarcinoma Non-Small-Cell LungBiomarkers TumorNon-Small Cell Lung Cancer; BiomarkersHumansFemaleBiomarkersAgedNeoplasm Staging
researchProduct

Solitary splenic metastasis from nasopharyngeal carcinoma: a case report and systematic review of the literature

2016

Background: Solitary splenic metastases are a rare occurrence, and the nasopharyngeal carcinoma represents one of the most uncommon primary sources. The present study aimed to describe a rare case of a solitary single splenic metastasis from nasopharyngeal carcinoma and to assess the number of cases of isolated nasopharyngeal carcinoma metastases to the spleen reported in the literature. Main body: We describe the case of a 56-year-old man with a history of nasopharyngeal carcinoma and complete remission after chemo-radiotherapy. Three months after complete remission, positron emission tomography/ computed tomography scan revealed a hypermetabolic splenic lesion without increased metabolic …

MaleHerpesvirus 4 HumanPathologymedicine.medical_specialtySplenic metastasisBiopsymedicine.medical_treatmentSplenectomyNasopharyngeal neoplasmSplenic metastasis Nasopharyngeal carcinoma Systematic reviewSplenic NeoplasmReview03 medical and health sciencesRare Diseases0302 clinical medicineSurgical oncologyNasopharynxPositron Emission Tomography Computed TomographyBiopsymedicineCarcinomaHumansNeoadjuvant therapyNeoplasm StagingNasopharyngeal Carcinomamedicine.diagnostic_testbusiness.industrySplenic NeoplasmsCarcinomaNasopharyngeal NeoplasmsChemoradiotherapyMiddle Agedmedicine.diseaseMagnetic Resonance ImagingNeoadjuvant TherapySettore MED/18 - Chirurgia GeneraleTreatment OutcomeOncologyNasopharyngeal carcinomaLymphatic Metastasis030220 oncology & carcinogenesisSystematic reviewSplenectomyLaparoscopy030211 gastroenterology & hepatologySurgerybusinessWorld Journal of Surgical Oncology
researchProduct

Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual…

2014

Background Multiple myeloma is an incurable disease characterized by proliferation of clonal malignant plasma cells (CPCs), which can be immunophenotypically distinguished from polyclonal plasma cells (PPCs) by multiparameter flow cytometry (MFC). The utility of PPCs analysis in detecting prognostic and predictive information is still a matter of debate. Methods: we tested the ability of 11 MFC markers in detecting differences in the immunophenotype of CPCs and PPCs among patients in various disease stages; we verified if these markers could be associated with disease stage/response to therapy despite the role of clinical parameters. Results: significant changes in the expression of markers…

MaleHistologyIntegrin alpha4Antigens CD19Plasma CellsAntineoplastic AgentsSettore MED/42 - Igiene Generale E ApplicataImmunophenotypingMonoclonal gammopathieRecurrenceMultiple myelomaHumansAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleMonoclonal gammopathies; Multiparameter flow cytometry; Multiple myeloma; Cell Biology; HistologyCell BiologyMiddle AgedCD58 AntigensFlow CytometryPrognosisCD56 AntigenClone CellsMultiparameter flow cytometryTreatment OutcomeGene Expression RegulationLeukocyte Common AntigensRegression AnalysisFemaleBiomarkers
researchProduct

Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European rand…

2021

Abstract Background In colon cancer (CC), surgery remains the mainstay of treatment with curative intent. Despite several clinical trials comparing open and laparoscopic approaches, data on long-term outcomes for stage III CC are lacking. Methods This post-hoc analysis of the European PETACC8 randomized phase 3 trial included patients from 340 sites between December 2005 and November 2009, with long follow-up (median 7.56 years). Patients were randomly assigned to FOLFOX or FOLFOX+cetuximab after colonic resection. The surgical approach was left to the referring surgeon's discretion. Results Among 2555 patients included, 1796 (70.29%) were operated on by open surgery and 759 (29.71%) by lap…

MaleLaparoscopic surgerymedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLeucovorinCetuximabAntineoplastic AgentsDisease-Free Survivallaw.invention03 medical and health sciences0302 clinical medicineFOLFOXRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansStage (cooking)Propensity ScoreLaparoscopyColectomyAgedNeoplasm StagingColectomyHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyPrognosismedicine.diseaseSurgeryEuropeSurvival RateClinical trialTreatment Outcome030220 oncology & carcinogenesisColonic NeoplasmsMultivariate AnalysisFemaleLaparoscopy030211 gastroenterology & hepatologyFluorouracilbusinessFollow-Up Studiesmedicine.drugDigestive and Liver Disease
researchProduct

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.

2022

Treatment for hepatocellular carcinoma (HCC) has experienced major advancements since the last update of the official Barcelona Clinic Liver Cancer (BCLC) prognosis and treatment strategy published in 2018. Advancements in the field have emerged in all areas, but in this manuscript, we present those that have primed a change in the strategy and comment why some encouraging data in select interventions are still considered immature and in need of further research to gain their incorporation into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that is needed to take clinical decisions in individual patients so that the rec…

MaleLiver CancerPrognosis predictionmedicine.medical_specialtyCarcinoma HepatocellularTare weightliver transplantation TACEAFPClinical Trials and Supportive ActivitiesClinical SciencesPsychological interventionSeverity of Illness IndexablationsurvivalArticleTAREsurgeryRare DiseasesClinical ResearchMedicineHepatectomyHumansHCCIntensive care medicineStaging systemNeoplasm StagingCancerHepatologyGastroenterology & Hepatologybusiness.industryLiver DiseaseCarcinomaLiver NeoplasmsALBI scoreHepatocellularsystemic treatmentMiddle Agedmedicine.diseasePrognosisBCLCGood Health and Well BeingHepatocellular carcinomaPublic Health and Health ServicesTreatment strategyFemalebusinessLiver cancerDigestive Diseases
researchProduct